Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.46 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
| ▸ | FNTB | P49356 | 2/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | NPY4R | P50391 | 1/20 | 0.45 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630512 | 0.92 | BACE1 (0.50) | BACE1BACE2OPRD1FNTAFNTB | |
| SCHEMBL30320511 | 0.90 | BACE1 (0.47) | BACE1BACE2IL23RFNTAFNTB | |
| SCHEMBL29567955 | 0.90 | OPRD1 (0.49) | BACE1BACE2OPRD1NPY1RNPY2R | |
| SCHEMBL38664549 | 0.88 | GLP1R (0.52) | BACE1IL23RKISS1R | |
| SCHEMBL29592512 | 0.86 | BACE1 (0.55) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL31345044 | 0.86 | BACE1 (0.55) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL29630763 | 0.85 | NPY4R (0.51) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL29567343 | 0.85 | NPY1R (0.50) | BACE1BACE2OPRD1NPY1RNPY2R | |
| SCHEMBL30311095 | 0.85 | ENPEP (0.57) | BACE1BACE2FNTAFNTBNPY1R | |
| SCHEMBL29558363 | 0.85 | ENPEP (0.52) | BACE1BACE2FNTAFNTBNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | BACE1 530/4885BACE2 1048/4885OPRD1 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.